NO20026032D0 - Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer - Google Patents

Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer

Info

Publication number
NO20026032D0
NO20026032D0 NO20026032A NO20026032A NO20026032D0 NO 20026032 D0 NO20026032 D0 NO 20026032D0 NO 20026032 A NO20026032 A NO 20026032A NO 20026032 A NO20026032 A NO 20026032A NO 20026032 D0 NO20026032 D0 NO 20026032D0
Authority
NO
Norway
Prior art keywords
annealed
farnesyltransferase inhibiting
quinoline enantiomer
enantiomer
quinoline
Prior art date
Application number
NO20026032A
Other languages
English (en)
Other versions
NO324494B1 (no
NO20026032L (no
Inventor
Marc Gaston Venet
Patrick Rene Angibaud
David William End
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20026032D0 publication Critical patent/NO20026032D0/no
Publication of NO20026032L publication Critical patent/NO20026032L/no
Publication of NO324494B1 publication Critical patent/NO324494B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20026032A 2000-06-22 2002-12-16 Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer, farmasoytisk sammensetning inneholdende denne og dens fremstilling, samt anvendelse av forbindelsen NO324494B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (3)

Publication Number Publication Date
NO20026032D0 true NO20026032D0 (no) 2002-12-16
NO20026032L NO20026032L (no) 2002-12-16
NO324494B1 NO324494B1 (no) 2007-10-29

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026032A NO324494B1 (no) 2000-06-22 2002-12-16 Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer, farmasoytisk sammensetning inneholdende denne og dens fremstilling, samt anvendelse av forbindelsen

Country Status (33)

Country Link
US (3) US20030114471A1 (no)
EP (1) EP1296984B1 (no)
JP (1) JP4919575B2 (no)
KR (2) KR100846370B1 (no)
CN (1) CN1207296C (no)
AR (1) AR030704A1 (no)
AT (1) ATE294804T1 (no)
AU (3) AU2001263962B2 (no)
BG (1) BG65894B1 (no)
BR (1) BRPI0111743B8 (no)
CA (1) CA2410232C (no)
CZ (1) CZ295278B6 (no)
DE (1) DE60110592T2 (no)
EA (1) EA005065B1 (no)
EE (1) EE04966B1 (no)
EG (1) EG24180A (no)
ES (1) ES2241830T3 (no)
HR (1) HRP20020989B1 (no)
HU (1) HU229095B1 (no)
IL (2) IL153560A0 (no)
IS (1) IS2596B (no)
JO (1) JO2361B1 (no)
MX (1) MXPA02012845A (no)
MY (1) MY127734A (no)
NO (1) NO324494B1 (no)
NZ (1) NZ522481A (no)
PA (1) PA8519501A1 (no)
PL (1) PL209521B1 (no)
SA (1) SA01220349B1 (no)
SK (1) SK285699B6 (no)
UA (1) UA73572C2 (no)
WO (1) WO2001098302A1 (no)
ZA (1) ZA200210305B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
DE60307616T2 (de) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
HUE044698T2 (hu) 2015-08-17 2019-11-28 Kura Oncology Inc Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
JP2000507955A (ja) 1996-04-03 2000-06-27 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
RU2205831C2 (ru) * 1997-04-25 2003-06-10 Янссен Фармацевтика Н.В. Хиназолиноны, ингибирующие фарнезилтрансферазу
CN100525766C (zh) 1997-06-02 2009-08-12 詹森药业有限公司 用作平滑肌细胞增殖抑制剂的（咪唑-5-基）甲基-2-喹啉酮衍生物
PL193464B1 (pl) * 1998-07-06 2007-02-28 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
TR200101343T2 (tr) * 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
DE69923849T2 (de) * 1998-08-27 2006-01-12 Pfizer Products Inc., Groton Quinolin-2-on-derivate verwendbar als antikrebsmittel
DK1140935T3 (da) * 1998-12-23 2003-09-01 Janssen Pharmaceutica Nv 1,2-anellerede quinolinderivater
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
SK11002001A3 (sk) * 1999-02-11 2002-05-09 Pfizer Products Inc. Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
ATE375794T1 (de) * 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives

Also Published As

Publication number Publication date
IS6590A (is) 2002-10-25
HUP0300872A2 (hu) 2003-07-28
HK1058363A1 (en) 2004-05-14
BR0111743A (pt) 2003-07-08
EP1296984B1 (en) 2005-05-04
US20080114009A1 (en) 2008-05-15
CA2410232A1 (en) 2001-12-27
EP1296984A1 (en) 2003-04-02
HRP20020989B1 (hr) 2011-05-31
AU2001263962B2 (en) 2006-07-20
MXPA02012845A (es) 2003-05-15
CZ2003114A3 (cs) 2003-05-14
AU6396201A (en) 2002-01-02
KR100846370B1 (ko) 2008-07-15
AR030704A1 (es) 2003-09-03
ATE294804T1 (de) 2005-05-15
CZ295278B6 (cs) 2005-06-15
AU2006220405A1 (en) 2006-10-12
HUP0300872A3 (en) 2004-11-29
KR20030009463A (ko) 2003-01-29
US8318753B2 (en) 2012-11-27
MY127734A (en) 2006-12-29
CN1437601A (zh) 2003-08-20
CN1207296C (zh) 2005-06-22
BRPI0111743B1 (pt) 2019-03-26
IS2596B (is) 2010-03-15
US20070259902A1 (en) 2007-11-08
BRPI0111743B8 (pt) 2021-05-25
KR20070121847A (ko) 2007-12-27
PL358918A1 (en) 2004-08-23
JP2004501153A (ja) 2004-01-15
DE60110592T2 (de) 2006-01-19
EA005065B1 (ru) 2004-10-28
NZ522481A (en) 2004-09-24
DE60110592D1 (de) 2005-06-09
EG24180A (en) 2008-09-28
BG107310A (bg) 2003-07-31
HU229095B1 (en) 2013-07-29
EA200300048A1 (ru) 2003-04-24
SK502003A3 (en) 2003-05-02
PL209521B1 (pl) 2011-09-30
KR100831940B1 (ko) 2008-05-23
PA8519501A1 (es) 2002-08-29
CA2410232C (en) 2008-10-07
AU2006220405B2 (en) 2009-05-21
EE200200695A (et) 2004-06-15
BG65894B1 (bg) 2010-04-30
IL153560A0 (en) 2003-07-06
ES2241830T3 (es) 2005-11-01
NO324494B1 (no) 2007-10-29
JO2361B1 (en) 2006-12-12
ZA200210305B (en) 2004-03-19
JP4919575B2 (ja) 2012-04-18
NO20026032L (no) 2002-12-16
HRP20020989A2 (en) 2005-02-28
US8329714B2 (en) 2012-12-11
WO2001098302A1 (en) 2001-12-27
UA73572C2 (en) 2005-08-15
SK285699B6 (sk) 2007-06-07
IL153560A (en) 2011-06-30
US20030114471A1 (en) 2003-06-19
EE04966B1 (et) 2008-02-15
SA01220349B1 (ar) 2007-01-23

Similar Documents

Publication Publication Date Title
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
WO2005011653A3 (en) Pyridazine derivatives and their use as therapeutic agents
GEP20053511B (en) ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
IS6970A (is) Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
NO20026032D0 (no) Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
DE50211929D1 (en) Pyrimidinderivate
MXPA02008870A (es) Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
WO2003066806A3 (en) Therapeutic use of aziridino compounds

Legal Events

Date Code Title Description
MK1K Patent expired